The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2022 | Myeloma Patients Europe: aims & projects
Hans Scheurer, MSc, European Medicines Agency, Amsterdam, Netherlands and Myeloma Patients Europe, Brussels, Belgium, gives an overview of Myeloma Patients Europe (MPE)’s structure, aims, and its ongoing work in facilitating access to novel treatments such as chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies to patients with multiple myeloma, and ensuring clinical trials are patient-friendly and address unmet needs expressed by the patient community. Mr Scheurer also highlights MPE’s education program for patient advocates designed to improve their knowledge of healthcare. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
